C

Cutia Therapeutics
HKEX:2487

Watchlist Manager
Cutia Therapeutics
HKEX:2487
Watchlist
Price: 10.24 HKD 5.35% Market Closed
Market Cap: 3.3B HKD

Wall Street
Price Targets

Price Targets Summary
Cutia Therapeutics

Wall Street analysts forecast Cutia Therapeutics stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 8.83 HKD with a low forecast of 8.08 HKD and a high forecast of 9.78 HKD.

Lowest
Price Target
8.08 HKD
21% Downside
Average
Price Target
8.83 HKD
14% Downside
Highest
Price Target
9.78 HKD
5% Downside
Cutia Therapeutics Competitors:
Price Targets
ADCT
ADC Therapeutics SA
171% Upside
ACAD
ACADIA Pharmaceuticals Inc
28% Upside
BONEX
Bonesupport Holding AB
34% Upside
BCAX
Bicara Therapeutics Inc
185% Upside
4597
Solasia Pharma KK
20% Upside
INCY
Incyte Corp
13% Upside
688687
Beijing Kawin Technology Share-holding Co Ltd
55% Upside
VRTX
Vertex Pharmaceuticals Inc
11% Upside

Revenue
Forecast

Revenue Estimate
Cutia Therapeutics

For the last 2 years the compound annual growth rate for Cutia Therapeutics's revenue is 396%. The projected CAGR for the next 3 years is 70%.

396%
Past Growth
70%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Cutia Therapeutics

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Cutia Therapeutics

N/A
Past Growth
N/A
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is Cutia Therapeutics's stock price target?
Price Target
8.83 HKD

According to Wall Street analysts, the average 1-year price target for Cutia Therapeutics is 8.83 HKD with a low forecast of 8.08 HKD and a high forecast of 9.78 HKD.

What is Cutia Therapeutics's Revenue forecast?
Projected CAGR
70%

For the last 2 years the compound annual growth rate for Cutia Therapeutics's revenue is 396%. The projected CAGR for the next 3 years is 70%.

Back to Top